Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Humalog Kwikpen - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Humalog Kwikpen

Approved

STANDARD

Humalog Kwikpen

Eli Lilly Italia S.p.A.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 93019d2a5b2929c5
Company: Eli Lilly Italia S.p.A.
Type: Standard

Approval Details

Approval Id: 93019d2a5b2929c5
Drug Approval Philippines Name: Humalog Kwikpen
Product Name: Humalog Kwikpen
Registration Number: BR-1053
Brand Name: Humalog Kwikpen
Generic Name: Insulin Lispro (rDNA origin)
Dosage Form: Solution for Injection (IM/IV/SC)
Dosage Strength: 100 units/mL
Manufacturer: Eli Lilly Italia S.p.A.
Importer: Zuellig Pharma Corporation
Issuance Date: 25 October 2022
Expiry Date: 25 October 2027
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

93019d2a5b2929c5

Type

Standard

Back to Philippines FDA Approvals